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Vaccine Technologies
• Advancing technologies to improve vaccine
performance and delivery.

Vaccine Technologies:
Three Areas of Focus
• Cold chain technologies

• Delivery technologies

• Formulation and stabilization technologies

Introduction
• For more than a decade, PATH has been exploring
both the technical and commercial feasibility of
stabilizing vaccines for use in developing countries.

• To date, we have conducted research on 7 antigen
types with 11 vaccine producers and 22 technical
collaborators.
• This presentation will summarize lessons learned over
the past 10 years.
• Funding: Bill & Melinda Gates Foundation.
Kristensen D. Chen D. Stabilization of vaccines: Lessons learned. Human
Vaccines. 2010;6:229-231.

Stability Profile of Current Vaccines
Vaccines

Lesson 1: Integrate stabilization
efforts into early vaccine
development.

Integrate Stabilization Efforts Early

• Once a vaccine has an established record of safety
and clinical efficacy, there are risks and costs
associated with reformulation.
• Improvements in vaccine stability will almost always
be less expensive during initial vaccine development
than after regulatory approval.

Lesson 2: There are circumstances
where it makes sense to stabilize
existing vaccines.

Stabilizing Existing Vaccines Can Make
Sense When:
• Stability of the product is unacceptable or inferior to
other marketed products, e.g., requires frozen storage.

• Reformulation is needed for other reasons, e.g., a
change in antigen concentration or production process
or inclusion of an additional antigen.
• Proof of principle is needed for a new stabilization
method. New technologies are easier to assess and
demonstrate with an established vaccine.

Lesson 3: Freeze stabilization is
possible for vaccines containing
aluminum adjuvants.

Freeze Sensitivity of Vaccines
• Aluminum salt adjuvants are the most prevalent
adjuvants in human vaccines.
• Aluminum adjuvants irreversibly agglomerate when
frozen then thawed, reducing vaccine potency.
• There are several causes of accidental freezing, e.g.:
– malfunctioning or inappropriate refrigeration equipment
– use of cold packs during shipping that are frozen before
use
– low ambient temperatures during shipping

Freeze Sensitivity of Vaccines
• Losses due to freeze damage stress already
underfunded vaccine programs in developing
countries.

US CDC estimates that the federal
Vaccines for Children program
alone incurs more than $20 million
in vaccine waste annually from
accidental freezing.

Meta-Analysis of Vaccine Exposure to
Freezing Underscores Problem and Need

• Meta-analysis of 33 studies (Matthias, et al, Vaccine. 2007;25:3980-3986).
• 14% to 35% of vaccines were exposed to freezing temperatures.
• More rigorous study designs detected more freeze damage.

Cold Chain Temperature Studies:
PATH / WHO Protocol
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Protecting Vaccines From Freeze Damage
• Aluminum adjuvant-containing vaccines can be
protected from freeze damage by inclusion of GRAS
excipients (propylene glycol, polyethylene glycol 300,
or glycerin).
• PATH and collaborators have validated protection with
hepatitis B, DTP, and pentavalent (DTP-hepatitis BHib) vaccines.

Freeze Stabilization of Hepatitis B Vaccine

Immunogenicity of vaccine samples in mice following storage at
4°C or three -20 C/room temperature freeze-thaw cycles, with
and without freeze-protecting excipients.
Jones Braun, et al. Vaccine. 2009; 27:72–79.

Vaccine Freeze-Protection Technology
Is Available to All Companies
• PATH estimates freeze-protecting excipients (e.g.,
propylene glycol) add only US$0.001 of cost per dose.
• Two vaccine producers are incorporating the freezeprotection technology into childhood vaccines.
• PATH has placed the freeze-protection technology in
the public domain for use without charge by all vaccine
producers.
• Freeze protection should be considered for all new
alum-adjuvanted vaccines.
• PATH staff are available to provide information and
assistance.

Lesson 4: Heat stabilization requires
a more customized approach, and
results will be variable.

Example 1: Heat- and Freeze-Stable Liquid
Hepatitis B Vaccine: 12-Month Stability at 37 C
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Jones Braun, et al. Vaccine. 2009;27:4609-4614.

Example 2: Spray-Dried Measles Vaccine
• Most commercial lyophilized measles products lose
greater than 1 log10 virus titer within one week of
storage at 37 C (exception is GSK’s Rimevax).
• PATH and our collaborators have shown that spray
drying of measles vaccine has a lower process loss
than freeze drying or foam drying.
• Spray drying process parameters, residual moisture,
pH, surfactants, excipients, and divalent cations used
were systematically examined for effect on process
loss and storage stability.

Example 2: Spray Dried Measles Vaccine:
8 weeks stability at 37 C
• Result: The optimized spray-dried formulation
exhibited a loss of 0.9 log TCID50 at 37 C in 8 weeks.
• Best-performing formulation: 17% w/v trehalosesucrose; 50 mM KPO4, 4% w/v L-arginine; 1.25% wt.
glycerol; 4% w/v human serum albumin; 1-4 mM
CaCl2; 1-4 mM ZnCl2; pH 6.0.

• Bottom line: This is a meaningful improvement in
stability over some commercial freeze-dried measles
products, but only an incremental improvement in
stability over Rimevax (time to 1 log10 loss = 5 weeks).
Ohtake, et al. Vaccine. 2010;28:1275-1284.

Lesson 5: The full benefits of heatstable vaccines will only be realized
after changes are made to storage
guidelines.

Cold chain storage in an Asian country - WHO

Controlled Temperature Chain
• All vaccines should be kept in a controlled temperature
chain (CTC).
– Traditionally, this has been the +2 C to +8oC range, known as
the cold chain.
– Work is underway to label some products for higher temperature
storage.

• Many vaccines are quite heat stable.
– Could be stored safely above 2 C to 8 C in CTC.
– Storage guidelines need to be appropriate to the vaccine's heat
stability profile.
– Vaccine vial monitors can be used to help ensure against
excessive heat exposure.

Precedents Exist for Vaccines To Be Stored
at Controlled Room Temperature
• NeisVac-C® Meningococcal C Vaccine - Baxter, under
license to GSK - Canadian product insert:
– Store at 2°C to 8°C.

– Within the indicated shelf life the product may be stored at
room temperature (up to +25°C) for a single period not
exceeding 9 months.

• Dukoral® Cholera Vaccine - Sanofi Pasteur - Canadian
product insert:
– Store at 2°C to 8°C.
– The vaccine can be stored at room temperature (<27°C) for
up to 2 weeks on one occasion only.

Experience Using Vaccines
Outside of Refrigerated Storage
• Multiple studies have reported that hepatitis B vaccine
used for birth dose can be stored outside of
refrigerated storage with no effect on seroconversion
rates. (Data from China, Indonesia, and Vietnam.)
Wang, et al. Bull. World Health Org. 2007;85:649-732.
Sutanto, et al. Bull. World Health Org. 1999;77:119-126.
Hipgrave, et al. Journal Trop. Med. and Hygiene. 2006;74:225-260.

• Meningococcal group C vaccines have been stored at
controlled room temperature for 6 months prior to
administration, with no effect on immune response.
Schondorf, et al. Vaccine. 2007;25:1175-1182.

Four Steams of Work Needed for Success
COUNTRY-LEVEL EVIDENCE
- Identifying strategies and conditions
where ambient temperature storage
makes sense.

CHANGES TO STORAGE
GUIDELINES
- Working to license vaccines, esp. new
vaccines, to their true stability.

TEMPERATURE MONITORING
- Vaccine vial monitors (VVM),
threshold heat indicators, electronic
temperature monitors.

PROGRAMMATIC GUIDELINES
- Protocols.
- Training.

Controlled
Temperature
Chain
Adoption

Preferred Product Profile for Vaccines
• Developed by the Vaccine Presentation and Packaging
Advisory Group (VPPAG) - led by WHO with input from
public health entities, nonprofits, governments agencies, and
industry.

• Among the recommendations in VPPAG’s new Preferred
Product Profile:
- Maximize heat and freeze stability.

- License products for highertemperature storage.
* VPPAG membership includes GAVI, PATH, UNICEF

Supply Division and Programme Division, WHO
Expanded Programme on Immunization, US CDC,
among many others.

Lesson 6: Trade-offs may need to be

made between the heat stability and
the format characteristics of a
vaccine.

Heat Stability vs. Vaccine Format
• Some heat stability improvements result in suboptimal
product formats, while others enable new, beneficial
formats.
• Trade-off between stability and other attributes may be
encountered. For example, freeze-dried formulations
may have superior stability but can be more
complicated for users, with increased potential for
error. Packaging and shipping costs may be higher for
freeze-dried vaccines, and they can require more
storage space.

Heat Stability vs. Vaccine Format

• Heat stabilization technologies may yield superior
product formats. For example:
– Spray drying can yield free-flowing powders of
controlled particle size, facilitating aerosol delivery, dry
powder jet injection, coated microneedles, and erodible
implants.
– Freeze drying can be used to create fast-dissolving
tablets for convenient oral delivery.

Lesson 7: Products with enhanced
stability can benefit both vaccine
producers and purchasers.

Stable Vaccines:
Benefits to Vaccine Producers
• Enhance product features and
competitiveness.
• Potentially reduce costs through
bulk production efficiencies.
• Reduce risk of recalls when the
cold chain is breached during
shipment.
• Decrease shipping and storage
costs.

Stable Vaccines:
Benefits to Purchasers and End Users
• Widen the reach of immunization.
• Improve vaccine effectiveness.
• Reduce vaccine wastage and cost.
Levin, et al. Vaccine. 2007;25:9645-9657.

• Relieve the pressure on the cold
chain.
UNICEF

Conclusions
• Many stabilization technologies exist to protect
technologies from freeze and heat damage.
• Heat stabilization requires a customized approach, with
variable results.
• In general, it is easier and less expensive to address
vaccine stability during initial development, but
reformulation of existing vaccines is sometimes
warranted.
• Many existing vaccines could be stored at controlled
temperatures higher than the traditional cold chain, but
additional studies and policy changes are needed.
• Thermostable vaccines can benefit producers as well
as purchasers and end users.
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